You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

INBRIJA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Inbrija, and when can generic versions of Inbrija launch?

Inbrija is a drug marketed by Merz and is included in one NDA. There are five patents protecting this drug.

This drug has ninety-four patent family members in twenty-two countries.

The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.

DrugPatentWatch® Generic Entry Outlook for Inbrija

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for INBRIJA?
  • What are the global sales for INBRIJA?
  • What is Average Wholesale Price for INBRIJA?
Summary for INBRIJA
International Patents:94
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 134
Patent Applications: 4,149
Drug Prices: Drug price information for INBRIJA
What excipients (inactive ingredients) are in INBRIJA?INBRIJA excipients list
DailyMed Link:INBRIJA at DailyMed
Drug patent expirations by year for INBRIJA
Drug Prices for INBRIJA

See drug prices for INBRIJA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INBRIJA
Generic Entry Date for INBRIJA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INBRIJA

US Patents and Regulatory Information for INBRIJA

INBRIJA is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of INBRIJA is ⤷  Try for Free.

This potential generic entry date is based on patent ⤷  Try for Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for INBRIJA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
Merz INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for INBRIJA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Acorda Therapeutics Ireland Limited Inbrija levodopa EMEA/H/C/004786
Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Authorised no no no 2019-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for INBRIJA

When does loss-of-exclusivity occur for INBRIJA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13342246
Patent: High dose levodopa capsules for pulmonary use
Estimated Expiration: ⤷  Try for Free

Patent: 13342247
Patent: Dosator for filling a capsule with powder
Estimated Expiration: ⤷  Try for Free

Patent: 13342248
Patent: Ultra low density pulmonary powders
Estimated Expiration: ⤷  Try for Free

Patent: 17279626
Patent: Dosator For Filling A Capsule With Powder
Estimated Expiration: ⤷  Try for Free

Patent: 18204674
Patent: High Dose Levodopa Capsules For Pulmonary Use
Estimated Expiration: ⤷  Try for Free

Patent: 18222983
Patent: Ultra Low Density Pulmonary Powders
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 2015010601
Estimated Expiration: ⤷  Try for Free

Patent: 2015010603
Patent: CÁPSULAS DE LEVODOPA DE DOSE ALTA PARA O USO PULMONAR
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 90451
Patent: CAPSULES DE LEVODOPA A DOSE ELEVEE POUR UNE UTILISATION PULMONAIRE (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 90454
Patent: APPAREIL DE DOSAGE POUR REMPLIR UNE CAPSULE AVEC UNE POUDRE SECHE (DOSATOR FOR FILLING A CAPSULE WITH POWDER)
Estimated Expiration: ⤷  Try for Free

Patent: 90459
Patent: POUDRES PULMONAIRES DE DENSITE ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

China

Patent: 4918607
Patent: High dose levodopa capsules for pulmonary use
Estimated Expiration: ⤷  Try for Free

Patent: 5120843
Patent: Ultra low density pulmonary powders
Estimated Expiration: ⤷  Try for Free

Patent: 9106697
Patent: 用于肺部使用的高剂量左旋多巴胶囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 0833539
Patent: 超低密度的肺部粉末 (Ultra low density pulmonary powders)
Estimated Expiration: ⤷  Try for Free

Denmark

Patent: 16821
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 16821
Patent: CAPSULES DE LÉVODOPA À DOSE ÉLEVÉE POUR UNE UTILISATION PULMONAIRE (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 16826
Patent: POUDRES PULMONAIRES DE DENSITÉ ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 25611
Patent: APPAREIL DE DOSAGE POUR REMPLIR UNE CAPSULE AVEC UNE POUDRE SÈCHE (DOSATOR FOR FILLING A CAPSULE WITH POWDER)
Estimated Expiration: ⤷  Try for Free

Patent: 15679
Patent: CAPSULES DE LÉVODOPA À DOSE ÉLEVÉE POUR UNE UTILISATION PULMONAIRE (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 57301
Patent: POUDRES PULMONAIRES DE DENSITÉ ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Hong Kong

Patent: 12884
Patent: 超低密度的肺部粉末 (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 13186
Patent: 用於肺部使用的高劑量左旋多巴膠囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 13187
Patent: 超低密度的肺部粉末 (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 13535
Patent: 用粉末填充膠囊的劑量分配器 (DOSATOR FOR FILLING A CAPSULE WITH POWDER)
Estimated Expiration: ⤷  Try for Free

Patent: 14957
Patent: 用於肺部使用的高劑量左旋多巴膠囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 47786
Estimated Expiration: ⤷  Try for Free

Patent: 48501
Estimated Expiration: ⤷  Try for Free

Patent: 69808
Estimated Expiration: ⤷  Try for Free

Patent: 21629
Estimated Expiration: ⤷  Try for Free

Patent: 36834
Estimated Expiration: ⤷  Try for Free

Patent: 15536197
Patent: 乾燥粉末を含むカプセルを充填する投与装置
Estimated Expiration: ⤷  Try for Free

Patent: 15536988
Patent: 肺使用のための高服用量のレボドパを含むカプセル
Estimated Expiration: ⤷  Try for Free

Patent: 15536989
Patent: 超低密度肺粉剤
Estimated Expiration: ⤷  Try for Free

Patent: 18150355
Patent: 肺使用のための高服用量のレボドパを含むカプセル (CAPSULES CONTAINING HIGH DOSES OF LEVODOPA FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 18162258
Patent: 超低密度肺粉剤 (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 19213867
Patent: 乾燥粉末を含むカプセルを充填する投与装置 (DOSING APPARATUS FOR FILLING CAPSULE WITH DRY POWDER)
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 1008
Patent: POLVOS PULMONARES DE ULTRA BAJA DENSIDAD. (ULTRA LOW DENSITY PULMONARY POWDERS.)
Estimated Expiration: ⤷  Try for Free

Patent: 15005767
Patent: CÁPSULAS CON ALTAS DOSIS DE LEVODOPA PARA USO PULMONAR. (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE.)
Estimated Expiration: ⤷  Try for Free

Patent: 15005768
Patent: POLVOS PULMONARES DE ULTRA BAJA DENSIDAD. (ULTRA LOW DENSITY PULMONARY POWDERS.)
Estimated Expiration: ⤷  Try for Free

Patent: 20012506
Patent: CAPSULAS CON ALTAS DOSIS DE LEVODOPA PARA USO PULMONAR. (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE.)
Estimated Expiration: ⤷  Try for Free

New Zealand

Patent: 8682
Patent: Dosator apparatus for filling a capsule with dry powder
Estimated Expiration: ⤷  Try for Free

Patent: 8684
Patent: High dose levodopa capsules for pulmonary use
Estimated Expiration: ⤷  Try for Free

Patent: 3459
Patent: Dosator for filling a capsule with dry powder
Estimated Expiration: ⤷  Try for Free

Patent: 7376
Patent: High dose levodopa capsules for pulmonary use
Estimated Expiration: ⤷  Try for Free

Patent: 7378
Patent: Ultra low density pulmonary powders
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 16821
Estimated Expiration: ⤷  Try for Free

Portugal

Patent: 16821
Estimated Expiration: ⤷  Try for Free

Russian Federation

Patent: 70987
Patent: ПОРОШКИ ДЛЯ ИНГАЛЯЦИИ С УЛЬТРАНИЗКОЙ ПЛОТНОСТЬЮ (ULTRA LOW DENSITY INHALATION POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 76093
Patent: КАПСУЛЫ, СОДЕРЖАЩИЕ ВЫСОКИЕ ДОЗЫ ЛЕВОДОПЫ, ДЛЯ ПРИМЕНЕНИЯ ПУТЕМ ИНГАЛЯЦИИ (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 15121091
Patent: ПОРОШКИ ДЛЯ ИНГАЛЯЦИИ С УЛЬТРАНИЗКОЙ ПЛОТНОСТЬЮ
Estimated Expiration: ⤷  Try for Free

Patent: 15121092
Patent: КАПСУЛЫ, СОДЕРЖАЩИЕ ВЫСОКИЕ ДОЗЫ ЛЕВОДОПЫ, ДЛЯ ПРИМЕНЕНИЯ ПУТЕМ ИНГАЛЯЦИИ
Estimated Expiration: ⤷  Try for Free

Patent: 18144622
Patent: КАПСУЛЫ, СОДЕРЖАЩИЕ ВЫСОКИЕ ДОЗЫ ЛЕВОДОПЫ, ДЛЯ ПРИМЕНЕНИЯ ПУТЕМ ИНГАЛЯЦИИ
Estimated Expiration: ⤷  Try for Free

Singapore

Patent: 201706465X
Patent: HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE
Estimated Expiration: ⤷  Try for Free

Patent: 201707103S
Patent: ULTRA LOW DENSITY PULMONARY POWDERS
Estimated Expiration: ⤷  Try for Free

Patent: 202109328Q
Patent: HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE
Estimated Expiration: ⤷  Try for Free

Patent: 201503543P
Patent: HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE
Estimated Expiration: ⤷  Try for Free

Patent: 201503547T
Patent: ULTRA LOW DENSITY PULMONARY POWDERS
Estimated Expiration: ⤷  Try for Free

South Africa

Patent: 1504058
Patent: HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE
Estimated Expiration: ⤷  Try for Free

Patent: 1504060
Patent: ULTRA LOW DENSITY PULMONARY POWDERS
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 2257164
Estimated Expiration: ⤷  Try for Free

Patent: 2337781
Estimated Expiration: ⤷  Try for Free

Patent: 2389785
Estimated Expiration: ⤷  Try for Free

Patent: 150108816
Patent: ULTRA LOW DENSITY PULMONARY POWDERS
Estimated Expiration: ⤷  Try for Free

Patent: 150110480
Patent: 폐에서의 사용을 위한 고용량 레보도파 캡슐 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 210062730
Patent: 폐에서의 사용을 위한 고용량 레보도파 캡슐 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 210152020
Patent: 폐용 초저밀도 분말 (ULTRA LOW DENSITY PULMONARY POWDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 220054703
Patent: 폐에서의 사용을 위한 고용량 레보도파 캡슐 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Patent: 230116102
Patent: 폐에서의 사용을 위한 고용량 레보도파 캡슐 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 44153
Estimated Expiration: ⤷  Try for Free

Patent: 80271
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INBRIJA around the world.

Country Patent Number Title Estimated Expiration
Israel 153281 ⤷  Try for Free
Singapore 10201706465X HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE ⤷  Try for Free
Denmark 1381416 ⤷  Try for Free
Poland 374794 ⤷  Try for Free
Japan 4897198 ⤷  Try for Free
Singapore 11201503543P HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for INBRIJA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3209302 2023C/510 Belgium ⤷  Try for Free PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: BE660571 20220901
3209302 11/2023 Austria ⤷  Try for Free PRODUCT NAME: KOMBINATION VON FOSLEVODOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND FOSCARBIDOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: 141371 20220826
1613296 CR 2015 00042 Denmark ⤷  Try for Free PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
3209302 CR 2023 00015 Denmark ⤷  Try for Free PRODUCT NAME: KOMBINATION AF FOSLEVODOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG FOSCARBIDOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; NAT. REG. NO/DATE: 66549 (DK) 20221205; FIRST REG. NO/DATE: AT 141371 20220826
3209302 CA 2023 00015 Denmark ⤷  Try for Free PRODUCT NAME: KOMBINATION AF FOSLEVODOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG FOSCARBIDOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; NAT. REG. NO/DATE: 66549 (DK) 20221205; FIRST REG. NO/DATE: AT 141371 20220826
1613296 92782 Luxembourg ⤷  Try for Free PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for INBRIJA

Introduction

INBRIJA, a levodopa inhalation powder developed by Acorda Therapeutics, is a significant player in the treatment of Parkinson’s disease, particularly for managing OFF periods. Here, we delve into the market dynamics and financial trajectory of INBRIJA, highlighting key milestones, challenges, and future projections.

Market Position and Growth

INBRIJA currently enjoys a dominant market share within the on-demand treatment class for Parkinson’s disease, holding a 67% market share. This is largely due to its preference among healthcare professionals and patients over other on-demand treatments like apomorphine-based products[4].

U.S. Market

In the U.S., INBRIJA has shown consistent growth. For the quarter ended September 30, 2023, U.S. net revenue from INBRIJA was $8.1 million, a 4% increase compared to the same quarter in 2022. For the full year 2022, INBRIJA U.S. net revenue was $28 million, meeting the company's guidance targets[2].

International Expansion

Acorda Therapeutics has been actively expanding INBRIJA into international markets. The drug was launched in Germany in mid-2022 and in Spain in early 2023. For the third quarter of 2023, ex-U.S. INBRIJA net revenue was $1.4 million, primarily from sales in Spain. Discussions are ongoing for commercialization in additional EU markets and Asia, with expectations of increased ex-U.S. revenue in 2023 and 2024[2][4].

Financial Performance

Revenue Trends

  • 2022: INBRIJA global net revenue was $30.9 million, with $28 million from U.S. sales and $2.9 million from ex-U.S. sales. This represented a slight increase from the $29.6 million in U.S. sales in 2021[1].
  • 2023: For the third quarter, worldwide INBRIJA net revenue was $9.5 million, a 7% increase. The full-year 2023 guidance for INBRIJA U.S. net revenue has been revised to $34-$38 million, reflecting continued growth but at a slower pace than initially projected[2][5].

Cost Management and Efficiency

Acorda has made significant strides in reducing operating expenses. The renegotiation of manufacturing agreements with Catalent and the arbitration award related to AMPYRA have contributed to lower costs. For 2023, the adjusted operating expense (OPEX) guidance has been revised to $93-$98 million, down from the initial range of $93-$103 million[1][5].

Key Milestones and Initiatives

Launches and Partnerships

  • The successful launches in Germany and Spain have been crucial for expanding INBRIJA's global footprint. Partnerships, such as the one with Esteve, have facilitated these launches and are expected to drive future growth[1][3].
  • Acorda is also planning to launch Biopas in Latin America in early 2024, which is expected to add to the revenue stream[1].

Marketing and Sales Strategies

  • Acorda has implemented several high-potential initiatives to grow the INBRIJA business, including new brand campaigns for physicians and patients, expanding the use of an E-prescribing platform, and introducing a cash-pay option to improve patient access. The sales team has adopted a hyper-targeted call strategy to enhance sales performance[4].

Challenges and Opportunities

Market Competition

Despite its market share, INBRIJA faces competition from other on-demand treatments. However, healthcare professionals' preference for INBRIJA due to its safety and efficacy profile continues to be a strong advantage[4].

Patient Access

Less than 2% of the 380,000 people with Parkinson’s who experience OFF periods are actively on any on-demand treatment. This presents a significant opportunity for INBRIJA to expand its market by increasing awareness and access to the treatment[4].

Financial Guidance and Projections

2023 Financial Guidance

  • INBRIJA U.S. net revenue is expected to be $34-$38 million.
  • Adjusted OPEX is guided to be $93-$98 million.
  • The ending cash balance is expected to be $39-$44 million.
  • Despite the revised guidance, INBRIJA is expected to continue its growth trajectory, albeit at a slower pace than initially anticipated[2][5].

Long-Term Outlook

Acorda Therapeutics aims to be cash-flow positive in the future, with INBRIJA playing a central role in achieving this goal. The company's long-term plan includes continued expansion into new markets and maintaining fiscal discipline to ensure sustainable growth[4].

Key Takeaways

  • Market Dominance: INBRIJA holds a 67% market share in the on-demand treatment class for Parkinson’s disease.
  • Revenue Growth: INBRIJA has shown consistent revenue growth in the U.S. and is expanding into international markets.
  • Cost Efficiency: Acorda has successfully reduced operating expenses through renegotiated agreements and cost-saving initiatives.
  • Future Projections: INBRIJA is expected to continue growing, with a focus on expanding into new markets and improving patient access.

FAQs

1. What is INBRIJA, and how does it treat Parkinson’s disease? INBRIJA is a levodopa inhalation powder used to treat OFF periods in patients with Parkinson’s disease. It provides on-demand relief by delivering levodopa directly to the lungs.

2. What is the current market share of INBRIJA in the on-demand treatment class? INBRIJA currently holds a 67% market share within the on-demand treatment class for Parkinson’s disease[4].

3. Which international markets has INBRIJA been launched in? INBRIJA has been launched in Germany and Spain, with plans for further expansion into Latin America and other EU and Asian markets[1][3].

4. How has Acorda Therapeutics managed to reduce operating expenses for INBRIJA? Acorda has reduced operating expenses through the renegotiation of manufacturing agreements with Catalent, arbitration awards, and other cost-saving initiatives[1][5].

5. What are the financial guidance and projections for INBRIJA in 2023? For 2023, INBRIJA U.S. net revenue is expected to be $34-$38 million, with adjusted OPEX guided to be $93-$98 million and an ending cash balance of $39-$44 million[2][5].

Sources

  1. Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results - Acorda Therapeutics Investor News[1].
  2. Acorda Therapeutics Reports Third Quarter 2023 Financial Results - Acorda Therapeutics Investor News[2].
  3. Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results - Acorda Therapeutics Investor News[3].
  4. Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance - BioSpace[4].
  5. Acorda Therapeutics Reports Second Quarter 2023 Financial Results - Acorda Therapeutics Earnings Release[5].
Last updated: 2024-12-17

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.